Previsioni
Il prezzo obiettivo medio degli analisti è 64,98 € (+48,09%). La mediana è 64,71 € (+47,47%).
| Acquista |
13 |
| Mantieni |
2 |
| Vendi |
0 |
Discussioni nella community
Non ci sono ancora discussioni su questo asset.
Avvia discussioneNotizie Vai al feed delle notizie
Scholar Rock clarifies FDA requirements for ISEMBYLD, shares fall sharply
Scholar Rock confirmed that the FDA requires post‑marketing conditions for ISEMBYLD, including a study on safety in pregnancy and 15‑day adverse‑event reporting for bone fractures. Management had previously (and incorrectly) stated that no such conditions existed. The stock then fell 6.4% to $51.85 and declined 9.7% on the week. Scholar Rock said it will carry out the requested studies and reporting in line with FDA requirements; analysts subsequently adjusted ratings and price targets. » Altro su de.investing.com
FDA grants approval for ISEMBYLD; Scholar Rock stock rises
The FDA approved ISEMBYLD (apitegromab-mstn) as the first muscle-specific treatment for spinal muscular atrophy in adults and children aged two and older who are already receiving an SMN2-directed therapy. The news pushed Scholar Rock’s stock up about 9% pre-market to $60.45 and converts the company into a commercial biopharma company. Several analysts sharply raised price targets and reiterated buy ratings; apitegromab is projected to generate billions in sales by 2035. Scholar Rock reports roughly $492 million in cash and has independent fill-and-finish and manufacturing capabilities for the product launch. » Altro su de.investing.com
Scholar Rock receives FDA approval for Isembyld to treat SMA
The FDA has approved Isembyld (Apitegromab‑mstn) for the treatment of spinal muscular atrophy in patients aged two and older. The approval is based on the phase‑3 SAPPHIRE study, in which patients receiving Isembyld in addition to standard therapy showed a significant improvement on the Hammersmith scale after one year; 34.2% achieved an increase of at least three points versus 13.5% with placebo. The US commercial launch has begun, the stock climbed more than 14% to an all‑time high, and Scholar Rock is shifting from a clinical biotech company to a commercial drugmaker. » Altro su deraktionaer.de
Scholar Rock prepares for FDA decision on apitegromab
Weeks before the PDUFA date on September 30, 2026, Scholar Rock highlights late Phase III data on apitegromab as well as secured commercial production and go‑to‑market infrastructure. After an earlier Complete Response Letter over manufacturing issues, the company moved commercial fill‑finish production to an alternative site and says it has already produced commercial vials there. Management emphasizes statistically significant Phase III results, high treatment adherence, and prepared sales, nursing and patient‑support structures for the US, with plans for Europe and Japan. » Altro su de.investing.com
Scholar Rock nears approval for apitegromab
At the Cantor Fitzgerald Global Healthcare Conference, Scholar Rock said the FDA has identified compliance with manufacturing requirements as the only remaining approval hurdle and that the company has since established a contractually committed alternative fill-and-finish facility. The crucial PDUFA date is September 30, 2026; management is holding intensive talks with the FDA about labeling and safety data. Scholar Rock has roughly $500 million in cash, sees worldwide market potential in the billions, and expects initial but manageable reimbursement and market-access hurdles during the first three to five quarters after launch. » Altro su de.investing.com
Dati finanziari
Nell'ultimo trimestre, SCHOLAR ROCK HLDG DL-,001 ha registrato ricavi pari a 503,22K € e un utile netto di -94,68 Mln €
| (EUR) | settembre 2026 | YoY |
|---|---|---|
| Ricavi | 503,22K | - |
| Utile lordo | 496,16K | 101,15% |
| Utile netto | -94,68 Mln | 8,69% |
| EBITDA | -90,36 Mln | 5,55% |
Dati fondamentali
| Metrica | Valore |
|---|---|
Capitalizzazione di mercato | 5,35 Mld € |
Numero di azioni | 122 Mln |
Massimo/minimo a 52 settimane | 56,28 € - 35,26 € |
| Dividendi | No |
Beta | 0,62 |
Rapporto P/E | -14,95 |
Rapporto PEG | 28,66 |
Rapporto P/B | 37,77 |
Rapporto P/S | 10.301,85 |
Profilo aziendale
Scholar Rock Holding Corporation, una società biofarmaceutica, si concentra sulla scoperta e sviluppo di farmaci per il trattamento di gravi malattie in cui la segnalazione mediata da fattori di crescita proteici svolge un ruolo fondamentale. La società sviluppa Apitegromab, un inibitore dell'attivazione della miostatina latente che ha completato le sperimentazioni cliniche di Fase 3 per il trattamento dell'atrofia muscolare spinale; e SRK-181, che si trova in sperimentazioni cliniche di Fase 1 per il trattamento di tumori resistenti alle terapie con inibitori dei checkpoint, come le terapie con anticorpi anti-PD-1 o anti-PD-L1. Sta inoltre sviluppando un portafoglio di nuovi candidati farmaco con il potenziale di trasformare la vita dei pazienti affetti da una serie di gravi malattie, tra cui disturbi neuromuscolari, cancro e fibrosi. La società ha un accordo di collaborazione con Gilead Sciences, Inc. per scoprire e sviluppare specifici inibitori dell'attivazione del fattore di crescita trasformante beta per il trattamento delle malattie fibrotiche. Scholar Rock Holding Corporation è stata fondata nel 2012 e ha sede a Cambridge, Massachusetts.
| Nome | SCHOLAR ROCK HLDG DL-,001 |
| CEO | David L. Hallal |
| Sede centrale | Cambridge,
ma Stati Uniti |
| Sito web | |
| Settore | Beni di prima necessità |
| Industria | Prodotti alimentari |
| Quotazione in borsa | 25/05/2018 |
| Dipendenti | 289 |
Simboli di borsa
| Borsa | Simbolo |
|---|---|
NASDAQ | SRRK |
Frankfurt | 2QK.F |
Düsseldorf | 2QK.DU |
München | 2QK.MU |